UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM CB/A

(Amendment No. 2)

 

TENDER OFFER/RIGHTS OFFERING NOTIFICATION FORM

 

Please place an X in the box(es) to designate the appropriate rule provisions(s) relied upon to file this Form:

 

 

Securities Act Rule 801 (Rights Offering)

o

 

Securities Act Rule 802 (Exchange Offer)

x

 

Securities Act Rule 13e-4(h) (8) (Issuer Tender Offer)

o

 

Exchange Act Rule 14d-1(c) (Third Party Tender Offer)

o

 

Exchange Act Rule 14e-2(d) (Subject Company Response)

o

 

Filed or submitted in paper if permitted by Regulation S-T Rule 101(b)(8)

o

 

LIFEWATCH AG

(Name of Subject Company)

 

Not applicable

(Translation of Subject Company’s Name into English (if applicable)

 

Switzerland

(Jurisdiction of Subject Company’s Incorporation or Organization)

 

BIOTELEMETRY, INC.

(Name of Person(s) Furnishing Form)

 

Shares

(Title of Class of Subject Securities)

 

ISIN: CH0012815459

(CUSIP Number of Class of Securities (if applicable))

 

Dr. Stephan Rietiker, CEO

LifeWatch AG

Baarerstrasse 139

6300 Zug

Switzerland

Tel: 41 41 728 67 77

(Name, Address (including zip code) and Telephone Number
(including area code) of Person(s) Authorized to Receive Notices
and Communications on Behalf of Subject Company)

 

Copies to:

 

Peter Ferola

Laurie L. Green

Senior Vice President, General Counsel

Flora R. Perez, Esq.

and Secretary

Greenberg Traurig. P.A.

BioTelemetry, Inc.

401 E Las Olas Blvd.,

1000 Cedar Hollow Road

Suite 2000

Malvern, Pennsylvania 19355

Ft Lauderdale, Florida 33301

(610) 729-7000

(954) 765-0500

 

*

(Date Tender Offer/Rights Offering Commenced)

     

  

*      The main offer period is scheduled to start on May 10, 2017, unless the cooling-off period is extended by the Swiss Takeover Board.

 

 

 


 

This Amendment No. 2 to the Notification on Form CB furnished by BioTelemetry, Inc. (“BioTelemetry”), a Delaware corporation, on April 10, 2017, is being submitted to furnish an offer prospectus (the “Offer Prospectus”) relating to the previously announced Public Exchange and Cash Offer by Cardiac Monitoring Holding Company, LLC, a Delaware corporation and a subsidiary of BioTelemetry, to acquire all of the publicly held registered shares of LifeWatch AG, a company organized and existing under the laws of Switzerland.

 

PART I - INFORMATION SENT TO SECURITY HOLDERS

 

Item 1.         Home Jurisdiction Documents

 

(a)(i)                      Pre-Announcement of the Public Exchange and Cash Offer published on April 9, 2017 (the “Pre-Announcement”).*

 

(a)(ii)                   Amendment of April 13, 2017 to the Pre-Announcement.**

 

(a)(iii)                Offer Prospectus, dated April 24, 2017.

 

*   Previously furnished on Form CB on April 10, 2017.

** Previously furnished on Form CB/A on April 13, 2017.

 

Item 2.         Informational Legends

 

The legend required by Rule 802(b) under the Securities Act of 1933, as amended, is included in the Pre-Announcement, as amended, and the Offer Prospectus.

 

PART II - INFORMATION NOT REQUIRED TO BE SENT TO SECURITY HOLDERS

 

(a)(iv)               Press Release dated April 24, 2017.

 

PART III - CONSENT TO SERVICE OF PROCESS

 

Not applicable.

 

PART IV - SIGNATURES

 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

BioTelemetry, Inc.

 

 

 

 

 

By:

/s/ Peter F. Ferola

 

 

Peter F. Ferola

 

 

Senior Vice President and General Counsel

 

 

Date: April 25, 2017